vimarsana.com

Latest Breaking News On - Foreign currency impact - Page 1 : vimarsana.com

BD Reports Second Quarter Fiscal 2024 Financial Results

Margin Execution Drives Better Performance in Quarter and Higher Guidance for Fiscal 2024 Q2 revenue of $5.0 billion increased 4.6% as reported, 4.7% currency-neutral and 5.7% organicQ2 GAAP and.

United statesTom polenTroy kirkpatrickExchange commissionBd life sciencesMedication delivery solutionsCamtech healthBusiness group on healthMedication management solutionsDiagnostics solutionsAmerica most innovative companiesClinical solutionsEuropean union medical device regulationMargin execution drives better performanceHigher guidanceContinuing operations

Becton Dickinson and : Earnings Release Q2 FY24

1 Becton Drive Franklin Lakes, NJ 07417 www.bd.com Contacts: Investors: Adam Reiffe, Sr..

United statesFranklin lakesTroy kirkpatrickTom polenMedication management solutionsEuropean union medical device regulationMedication delivery solutionsBd life sciencesClinical solutionsCamtech healthBusiness group on healthAmerica most innovative companiesDiagnostics solutionsExchange commissionAdam reiffeInvestor relations

FMC Corporation announces third quarter results and confirms full-year outlook

Third quarter results significantly impacted by lower sales in Latin America, channel destocking in all regionsThird Quarter 2023 HighlightsRevenu.

United statesMark douglasExchange commissionPlant healthLatin americaPrior year quarterNorth americaRevenue changeSafe harbor provisionsPrivate securities litigation reform actAnnual reportMonths endedseptemberMonths ended septemberPakistani rupeeAdjusted earningsLand disposition

FMC Corporation delivers solid first quarter results and raises full-year adjusted EBITDA and adjusted EPS guidance

Strong pricing, accelerating new product introductions and cost discipline drove margin expansion in the quarterFirst Quarter 2023 HighlightsReven.

United statesAndean regionArgentina generalMark douglasExchange commissionPlant healthNorth americaLatin americaRevenue changeSafe harbor provisionsPrivate securities litigation reform actAnnual reportMonths ended marchPakistani rupeeAdjusted earningsForeign currency impact

AMGEN REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS

/PRNewswire/ Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2022. Key results include: Total revenues decreased 1% to $6.7.

Puerto ricoUnited statesJessica akopyanRoberta bradwayProvention bioDavidm reeseNational cancer instituteResearch developmentTherapeutics incArrakis therapeutics incTeneobio incWorld congress on insulin resistanceRegeneron pharmaceuticals incPlexium incAlexion pharmaceuticals incExchange commission

vimarsana © 2020. All Rights Reserved.